ASSESSMENT OF ELIGIBILITY of patients with primary hyperparathyroidism

(n=110) RANDOMIZATION of eligible patients with written informed consent

- (n=55) ALLOCATED TO EPLERENONE 25mg (once daily)
- (n=55) ALLOCATED TO PLACEBO (once daily)

STUDY VISIT 1

STUDY VISIT 2 (week 1) (serum potassium level and creatinine/GFR will be checked)

STUDY VISIT 3 (week 4)

STUDY VISIT 4 (week 5) (serum potassium level and creatinine/GFR will be checked)

STUDY VISIT 5 (week 8)
Primary outcome: iPTH
Secondary outcomes: 24-hour syst./diast. ABP, biomarkers of cardiovascular and bone diseases, 24-hour urinary protein/albumin in excretion, echocardiographic parameters of LV function and structure